ATHE Stock — Alterity Therapeutics Ltd

Alterity Therapeutics Ltd (ATHE)

Updated October 16, 2026.

ATHE is a Stock. Total return is -99.6% over the past 24.1 years, 1335.0 points behind SPY at 1235.4%.

Alterity Therapeutics Limited is a biopharmaceutical company based in Melbourne, Australia that develops drug candidates to treat neurodegenerative disorders, particularly Parkinson's disease and Multiple System Atrophy. The company's lead program, ATH434, has completed Phase II clinical trials for Parkinson's disease and is in Phase II development for multiple indications of Multiple System Atrophy; the company also operates a drug discovery platform to generate compounds targeting the underlying causes of neurological diseases. This is a clinical-stage biotech company with no current distributions and typical early-stage company characteristics.

ATHE performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.6% over the past 24.1 years, 1335.0 points behind SPY at 1235.4%. Over the past year its total return — price change plus distributions reinvested — is -45.8%. Its deepest 1-year drawdown was 55.5%.

ATHE key facts

Asset type

Stock

Asset class

Equity

Inception date

09/05/2002

Distribution frequency

None

Last close

$2.62 (as of 2026-10-16)

Market cap

$47,705,924

Average volume

55877.0

Beta

-0.005

Payout ratio

0.0%

EPS

$-0.90

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ATHE risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 55.5%.

Who may consider ATHE — and who may not

It is a weaker fit for investors who need monthly cash flow (ATHE does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ATHE

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions